'NCDs in Focus Act Now' Summit organized by Viatris

---
'NCDs in Focus Act Now' Summit organized by Viatris

The summit aimed to build synergies between healthcare professions and policy makers, addressing the challenges in the management of NCDs in Southeast Asia

BANGKOK, Dec. 19, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS): The 'NCDs in Focus Act Now' Summit was recently organised by global healthcare company, Viatris, in collaboration with the Thai Hypertension Society and the Thai NCD Alliance. The objective of the summit was to address the clinical practice challenges in the management of NCDs and understand patient journey gaps.  Themed, 'NCDs in Even More Focus Forum 2022', the event was chaired by Prof. Apichard Sukonthasarn, President Thai hypertension Society and Director Bangkok hospital, Chiang Mai. It consisted of a speaker symposium, panel discussions, best practice sharing and workshops by eminent regional experts in the field along with policy experts and multidisciplinary healthcare professional representatives from several countries in Southeast Asia (SEA).

The summit had a fivefold purpose –

  • Showcasing how clinical data is effective in addressing the current gaps and unmet needs in clinical practice
  • Providing a platform for sharing expertise and best practices to optimize patient care
  • Revisiting the post COVID challenges of cardiovascular disease (CVD) and mental health disorders (MHD) care
  • Providing insight into imminent policy and practice changes, innovative digital solutions that allow for better outcomes
  • Developing and understanding of the gaps in patient journey

Prof. Apichard Sukonthasarn said, "The summit gave healthcare professionals across Southeast Asia an understanding of where their country stands in comparison with the rest of Asia and Europe in terms of resilient healthcare systems. Learning from other countries and understanding their challenges will help us in developing best practices, influence healthcare policy and build resilient and sustainable healthcare systems for combating the NCD disease burden''.

Dr Debbie Ona, Consultant, St. Luke's Medical Center, Philippines said, "Such platforms provide healthcare professionals and other relevant stakeholders an opportunity to build synergies, understand the evolving landscape and drive positive outcomes through public and private collaborations. It is crucial for us to come together so that we can network, share our expertise, data and collaboratively design initiatives which can potentially influence healthcare policies in our home countries. In order to effectively tackle the growing NCD disease burden, we must develop sustainable programs which have a clear-cut call to action and measurable impact.''

She adds, "CVDs remain the top killer in Southeast Asia. There are several successful public and private initiatives to reduce premature deaths by identifying those at highest risk of CVDs and providing them access to appropriate treatment. Cross-sharing of these initiatives and their data will benefit other countries in the region."

Viatris works to nurture healthcare systems that can adapt and respond to patients' ever-changing needs, collaborating with medical associations, patient advocacy groups and academia to develop innovative, integrated solutions and programs to help strengthen both the delivery and quality of healthcare – ultimately, to reduce the burden of NCDs.

About Viatris

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, and a variety of over-the-counter consumer products. With approximately 37,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube.


Source: Viatris Inc. Related Stocks: NASDAQ:VTRS

Related News

menu
menu